HC Wainwright & Co. Maintains Buy on Aptose Biosciences, Raises Price Target to $23
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Joseph Pantginis maintains a 'Buy' rating on Aptose Biosciences (NASDAQ:APTO) and raises the price target from $12 to $23.
August 11, 2023 | 12:10 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Aptose Biosciences' price target has been raised from $12 to $23 by HC Wainwright & Co., maintaining a 'Buy' rating.
The news of a price target increase and maintained 'Buy' rating by a reputable analyst firm like HC Wainwright & Co. is likely to instill confidence in investors and could lead to a short-term increase in the stock price of Aptose Biosciences.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100